Novelty and Impact:
INTRODUCTION
Breast cancer (BC) is a heterogeneous disease that is routinely classified according to the immunohistochemical assessment of Estrogen and Progesterone Receptors (ER, PR), human epidermal growth factor receptor 2 (HER2) and Ki67 [1, 2] . Alternatively, gene expression profiling according to the prediction analysis of microarray (PAM) 50 assay [3] can subdivide BC into intrinsic subtypes characterized by differential prognosis, i.e. luminal A, luminal B, HER2 positive, basal-like and normal-like. Gene signatures useful for informing therapeutic choices have been developed for early stage BC [3, 4] , and the dependence on ER, PR or HER2 activity is currently exploited for the application of targeted therapies [1] which have considerably improved patients' survival. However, the identification of specific markers responsible for worse prognosis across all cell types, potentially amenable to targeted therapies, is still needful.
WNT signaling is mediated by the WNT family of ligands, which controls fundamental processes in embryonic development and adult tissue homeostasis [5, 6] . According to the specific ligand involved, WNT signal transduction is broadly classified into canonical, β-catenin dependent, and non-canonical pathways, although the observation that specific co-receptors combinations in distinct cellular contexts can shape the pathway regardless of ligand identity challenges this rigid classification [7, 8] . Aberrant WNT signaling has been amply implicated in malignant transformation, and WNT ligands are overexpressed in a variety of cancers correlating with tumor progression [9, 10] . In particular, aberrant activation of the β-catenin-independent Planar Cell Polarity (PCP) pathway, which plays important roles in defining cell shape, adhesion and movement acting via the c-Jun N-terminal kinase (JNK) [6, 10] , is involved in the progression of many solid tumours, including those of the breast [11, 12] . While transcriptional responses to the activation of beta-catenin-dependent WNT pathways are well characterized, those triggered by the PCP pathway are less well understood and have been mainly linked to the JNK-dependent activation of members of the AP1 family of transcription factors [13, 14] .
The small GTPase RhoU was identified as a WNT1 target gene, mediating tumor transformation and promoting cell migration/invasion by inhibiting the formation of focal adhesions [15, 16] . Unlike most GTPases, RhoU displays high intrinsic guanine nucleotide exchange activity and is largely found in a GTP-loaded state [17, 18] . Accordingly, its regulation mostly occurs at the transcriptional level [19] . Despite WNT1 being considered a canonical ligand, WNT1-induced RhoU transcription is β-catenin-independent and requires JNK activity instead, suggesting the involvement of the non-canonical PCP pathway [19] . However, the molecular mechanisms leading to WNT-mediated RhoU transcriptional activation are currently unknown. RhoU gene expression can also be controlled by Signal Transducer and Activator of Transcription (STAT) 3 [19] , a pleiotropic transcription factor activated downstream of many cytokines and growth factor receptors and playing a multitude of different roles in regulating cell proliferation/apoptosis, differentiation, migration and metabolism [20] [21] [22] . STAT3 is considered as an oncogene, since its aberrant constitutive activity is required for the survival and proliferation of a wide variety of primary tumors and tumor cell lines [20] [21] [22] [23] [24] .
Here, we identify the SP1 transcription factor as an essential mediator of RhoU transcriptional activation downstream of the WNT/PCP pathway, and we unveil a functional cooperation between WNT/PCP/JNK, RhoU, SP1 and STAT3 to promote cell motility in basal-like human breast tumor cells. In vivo binding of both SP1 and STAT3 strikingly defines genes included in the non-canonical WNT and the IL-6 pathways. This novel signature is significantly correlated with low survival in breast cancer and is enriched in basal-like patients, suggesting that co-activation of the WNT-PCP and STAT3 pathways drives tumor aggressiveness. constructs [6] were used to monitor WNT pathway activation.
MATERIALS AND METHODS

Cell lines and treatments. Stat3
Transient transfections, co-cultures with WNT-expressing cells (24 hours), luciferase and SEAP assays were performed essentially as previously described [19] . Briefly, transfections were performed with LipofectamineTM (Invitrogen, MA, USA) according to manufacturer's instructions.
Each construct was co-transfected at a 10:1 ratio with a vector expressing secreted embryonic alkaline phosphatase (SEAP) as an internal control for transfection efficiency.
MDA-MB-231 cells were stably infected with pLKO lentiviral vectors expressing two different shRNA sequences targeting RhoU (assays No 77507 and 48657, Thermo Fisher Scientific, Waltham, MA USA) or a scrambled sequence as a control, followed by puromycin selection (Sigma-Aldrich, Saint Louis, MO, USA, 1 µg/ml).
Chromatin immunoprecipitation assays.
ChIP experiments were performed as previously described [19] on three independent biological samples, using the following antibodies: anti-SP1 sc- β-globin primers:
Wound healing migration assay. In vitro wound healing assays were performed essentially as described by Liang et al. [26] , with some modifications. In brief, confluent cells in 60-mm dish were serum-starved O/N, followed by mitomycin A treatment (10 µg/ml) for two hours. The monolayer was then scraped with a sterile pipette tip, washed with PBS and incubated in fresh medium containing 3% FBS. Phase-contrast images were taken at the indicated times (Axiovert Protein extracts and immunoblotting. Whole protein extractions and immunoblotting were performed as described [19] using the following antibodies: anti-SP1 sc-59 (Santa Cruz Biotechnology, Santa Cruz, CA); mouse monoclonal anti-GFP and mouse monoclonal anti-vinculin (home-made production).
RNA extraction, retrotranscription and quantitative real-time PCR (qRT-PCR)
. These procedures were previously described [19] . qRT-PCR reactions were performed with the ABI Prism 7300 realtime PCR System (Applied Biosystems, Carlsbad, CA) using Platinum Quantitative or SYBR Green PCR SuperMix-UDG with ROX (Life Technologies, Carlsbad, CA). Primers and probes used are reported in Supporting Information Table 3 . The 18S rRNA pre-developed TaqMan assay (Applied Biosystems, Carlsbad, CA) was used as an internal control.
Statistical analysis.
Results were assessed for statistical significance by a standard two-tailed
Student's t test, using the GraphPad Prism 5 software (GraphPad Software Inc., San Diego, CA, USA). Statistically significant P values: P ≤ 0.05 (*), P ≤ 0.01 (**), P ≤ 0.001 (***).
Bioinformatics analysis
Total Binding Affinity (TBA). TBA was computed as described in [27, 28] 
ChIP-Seq data analysis
ChIP-Seq data were downloaded from the UCSC browser [29] . Peaks were filtered according to the absolute distance (5 Kb) from the closest gene. Genes displaying binding sites for both TFs were selected.
Gene set data. Genes related to WNT and STAT3 signaling were obtained either from published manually curated gene sets [30] [31] [32] [33] , or from the "Molecular Signatures Database" (IL6, MsigDB C2) [34] (http://www.broadinstitute.org/gsea/msigdb/index.jsp).
The SP1-S3 signature was defined as follows: genes defined by the ChIP-Seq data analysis were assessed for their enrichment with the above gene sets (Fisher exact test, p<0.05). A combined gene signature was obtained from the intersection between the two top-ranking signatures and the ChIP-Seq derived signature, obtaining 144 genes, listed in Supporting Information Table 4 ).
Survival analysis.
Time-to-event analyses were performed using the Kaplan-Meier method (R, survival package). Patients were subdivided in two groups according to the median value of the SP1-S3 score, defined as the sum of SP1-S3 gene expression for each patient. Unstratified log-rank statistics were used to evaluate the effect of the change in SP1-S3 score on overall survival.
Univariate analysis. All univariate analyses were performed using the glm R function to assess the relationship between the SP1-S3 score and clinical features using the univariate Gaussian distribution. Logistic regression was applied for binary variables (https://www.R-project.org).
Plots
All plots were made using ggplot2 [35] , survminer (https://CRAN.Rproject.org/package=survminer) and R base graphics.
RESULTS
RhoU expression can be induced by both canonical and non-canonical WNT ligands.
Our previous observation that the canonical WNT1 ligand triggers β-catenin-independent/JNK- Fig. 1A ), conferring however weaker induction as compared to the sequence extending to position -756. Sequence analysis did not reveal binding sites for transcription factors know to be involved in WNT/PCP-mediated transcription such as those belonging to the AP1 family [19] . Therefore, in order to identify WNT-responsive elements we subjected the -756
construct Linker Scanning mutagenesis. Surprisingly, none of the mutations tested could affect promoter inducibility (Supporting Information Fig. 1B ), suggesting that WNT-mediated RhoU induction does not depend on a single responsive element but requires the cooperation of disseminated sites within the responsive region.
WNT-mediated induction of the RhoU promoter requires JNK-dependent SP1 recruitment.
The failure to impair promoter inducibility with single mutations could be consistent with one or more TFs exhibiting diffused binding to the promoter due to high Total Binding Affinity (TBA), which considers the contribution of low-affinity binding sites to calculate the overall affinity of transcription factors for a chosen promoter region [27, 28, 36] . The TBA of the WNT-responsive RhoU promoter region for the TFs included in the JASPAR core vertebrata database was calculated (Supporting Information Table 5 ). Among high scoring TFs we focused our attention on SP1, known to play a major role in the transcription of GC-rich TATA-less promoters [37] . Although SP1 is mainly known as a basal activator of many housekeeping genes, it is also a target for JNKmediated phosphorylation, which in turn can modulate its transcriptional and DNA binding activities at specific promoters [37] [38] [39] [40] . We thus reasoned that WNT-activated JNK may mediate SP1 activation, enabling it to induce RhoU gene transcription via diffused binding to its promoter. SP1 involvement was confirmed by the observation that WNT-mediated RhoU mRNA induction was abolished by the SP1 inhibitor mithramycin A (Mit.A) (Figure 2A ), which could also suppress the WNT1-mediated induction of the RhoU promoter but not of the TOPflash control ( Figure 2B ).
Accordingly, ChIP analysis revealed strong in vivo binding of SP1 to the RhoU WNT-responsive promoter region following treatment with all three WNT ligands tested ( Figure 2C, D) . SP1 binding, undetectable in unstimulated cells, was abolished by both Mit.A treatment ( Figure 2C ) and JNK inhibition ( Figure 2D ). Thus, all tested WNT ligands can activate a non-canonical, JNKmediated pathway that leads to SP1 recruitment to the RhoU promoter, driving its transcriptional activation. Accordingly, treatment with all three WNTs could increase the ratio of phosphorylated versus non-phosphorylated SP1 in a JNK-dependent manner, as shown by the relative increased intensity of the slower migrating band, corresponding to phosphorylated SP1 (Figure 2E , F). As expected Mit.A, which binds to GC-rich regions inhibiting SP1 DNA binding activity, did not affect WNT-mediated SP1 phosphorylation.
Migration of MDA-MB-231 cells downstream of constitutively active WNT5a requires both JNK and SP1 activities and RhoU expression.
β-catenin-independent WNT signaling is often aberrantly activated in both tumor and stromal cells [11, 12, 41, 42] , promoting JNK-dependent invasion [11, 42] . To assess the functional role of RhoU in this context we analyzed the highly aggressive basal-like breast cancer cell line MDA-MB-231, whose motility and invasivity have been shown to require the expression of the non-canonical
WNT5a and WNT5b ligands [11, 42] . Indeed, as compared with the weakly motile MCF-7 cells, MDA-MB-231 cells express significantly higher levels of WNT5b and of the ROR1 co-receptor, implicated in the non canonical WNT pathway [43] ( Figure 3A) . Accordingly, RhoU expression was significantly higher in MDA-MB-231 cells, and fully dependent on both JNK and SP1 activities ( Figure 3A 
RhoU is also involved in mediating cell migration downstream of STAT3 signaling.
We recently identified RhoU as a STAT3 target gene downstream of gp130 cytokines, and reported a positive correlation between STAT3 activation and RhoU expression levels in a panel of human tumor cell lines, including MDA-MB-231 cells [19] . In order to investigate the role of RhoU in STAT3-induced migration, Stat3 -/-MEFs, which express very low RhoU levels and display impaired migration compared to their wild-type counterparts [19, 44] , were stably transfected with a doxycycline-inducible RhoU-GFP expression vector and treated with increasing doxycycline concentrations, obtaining dose-dependent RhoU induction (Supporting Information Fig. 2B ). RhoU expression could significantly rescue the defective migration of Stat3 -/-MEFs in a wound-healing assay ( Figure 4A,B) , demonstrating its involvement in STAT3-mediated migration. We then explored potential synergic effects between the WNT and STAT3 pathways in MDA-MB-231 cells.
Treatment with the STAT3 inhibitor S3I considerably reduced the levels of RhoU mRNA ( Figure   4C ), leading to impaired cell migration at 24 hours, in synergy with the JNK inhibitor (P<0.01) ( Figure 4D, E) . These data are in line with the idea that RhoU indeed represents a common mediator of STAT3 and non canonical WNT/SP1 functions, under both physiological and pathological conditions.
SP1 and STAT3 in vivo binding defines a subclass of genes belonging to non canonical WNT
or IL-6 pathway.
The TFs SP1 and STAT3, whose binding sites are often found close together in the regulatory regions of genes, are involved in several functions related to tumorigenesis including apoptosis, cell growth, angiogenesis, epithelial to mesenchymal transition (EMT) and invasion [45] .
In order to investigate the STAT3 and SP1 regulatory network and to identify genes potentially 5A ). Enrichment analysis of the genes presenting both STAT3 and SP1 binding in published gene sets involving the activation of either the STAT3 or the WNT pathways revealed a positive and significant enrichment (p< 0.05, Fisher exact test) for eight out of seventeen gene sets (Fig. 5B) .
The ChIP-Seq traces for two representative genes are shown in Figure 5C . Of note, a high percentage of the peaks is located between positions -1000 and +1000 with respect to the TSS of the corresponding gene(s) (~74% for SP1, 57% for STAT3), compatibly with a regulatory role of the binding (data not shown). Importantly, the two top-ranking gene sets according to significance were linked to IL-6 (Broad Institute) and to non canonical WNT [31] signaling pathways, respectively (IL-6, ~37% overlap, 32 out of 87 genes; non-canonical WNT, ~23% overlap, 113 out of 489 genes).
High expression of SP1 and STAT3 dual targets is associated with low survival in breast cancer.
We then assessed the functional relevance of combined STAT3 and SP1 activity in breast cancer. To this end, we examined the METABRIC breast cancer dataset [48] for the expression of a signature composed of the genes belonging to the IL-6 or the WNT non-canonical pathways characterized by in vivo binding of both STAT3 and SP1, as identified above, denominated the SP1-S3 signature ( Supporting Information Table 4 and Table 6 ). All profiled tumors (n=1982) where classified according to the cumulative expression of the SP1-S3 signature (SP1-S3 score, high and low). This score was significantly higher in basal-like tumors compared to other subtypes, in keeping with the known frequent activation of both STAT3 and WNT pathways in this subset (Supporting Information Fig. 3A ). Patients with a high SP1-S3 score displayed significantly shorter overall survival as compared to patients scored as low ( Fig 5D) . To exclude that this correlation was due to the contribution of basal-like tumors, which can predict shorter survival when considered as a whole versus all other subtypes (not shown), we repeated the survival analysis excluding basallike tumors. Even under these conditions, a high SP1-S3 score was still significantly predictive of poor prognosis, supporting the idea that SP1 and STAT3 can functionally cooperate to enhance tumor aggressiveness independently of the tumor subtype (Supporting Information Fig. 3B) . A high SP1-S3 score was also significantly positively associated with tumor grade, higher degree of lymph node positivity and chemotherapy treatment, and negatively correlated with age at diagnosis and ER positivity ( Fig 5E) .
DISCUSSION
Molecular classification of tumors based on gene signatures correlated with clinical history may guide prognosis, therapeutic choices and, finally, the development of novel specific therapies [4] . Both the WNT and the STAT3 pathways are often altered in solid tumors including breast cancer, correlating with enhanced tumor cells migration, invasion and metastasis [10, 49] . In an attempt to assess potential synergistic mechanisms between the two pathways, we focused on their common transcriptional target, the atypical small GTPase RhoU [19] . Our observation that RhoU induction via the JNK-dependent PCP pathway can be equally mediated by canonical and noncanonical WNT ligands suggests that this small GTPase may act as a common effector of both, expanding the scope for its potential relevance in mediating the pathogenic effects of disrupted WNT signaling.
Small GTPases belonging to the Rho family are well known to mediate downstream effects of the JNK/PCP pathway [50] that, although best characterized for its transcription-independent functions, is also known to lead to the transcriptional modulation of several genes, mainly via JNKdependent activation of members of the AP1 family of transcription factors [13, 14] . The finding that RhoU is one of these transcriptional targets expands the repertoire of Rho GTPases downstream of the pathway. Moreover, our data identify SP1 as a novel transcriptional mediator of the JNK/PCP non canonical pathway, since its JNK-dependent recruitment to the RhoU promoter is essential for transcriptional induction downstream of both canonical and non-canonical WNT ligands. Although our data cannot discriminate between direct or indirect JNK-mediated SP1 activation, several pieces of evidence implicate this factor in inducible transcription upon both JNK and MAPK-mediated phosphorylation [38] [39] [40] .
Our variants H2AX, essential for DNA repair and linked to chemoresistance in breast cancer [51] and H2AZ, whose high expression correlates with BC progression, lymph node metastasis and survival [52] . Other enriched categories are "Signal Transduction", "Cell Communication" and "Response to 
